Destiny Pharma. Share News (DEST)

TRADING UPDATES: Vela, Standard Life Investments up portfolio value

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Destiny Pharma appoints Yuri Martina as chief medical officer

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the appointment of Dr Yuri Martina as its chief medical officer on Tuesday.

EARNINGS UPDATES: Parsley Box widens loss; M Winkworth profit doubles

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Destiny Pharma raises GBP450,000 through open offer

Destiny Pharma PLC - a clinical-stage biotechnology company based in Brighton, England - Raises total gross proceeds of GBP450,000 through its open offer. Has conditionally raised total gross proceeds of GBP6.5 million through its placing, subscription, and open offer. Says it has applied for the admission of 12.9 million shares, consisting of 11.9 million placing shares, 140,000 subscription shares and 909,007 open offer shares.

IN BRIEF: Destiny Pharma to raise GBP7.0 million for asset trials

Destiny Pharma PLC - clinical-stage biotechnology company based in Brighton, England - Intends to raise GBP7.0 million through a placing of 11.9 million shares at 50 pence each, subscription for 140,000 shares and an open offer for 2.0 million shares.

Destiny Pharma to raise up to £7m in discounted fundraising

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma said on Tuesday that it was looking to raise up to £7m in a conditional fundraising to continue progress towards Phase 3 in its two lead clinical assets.

IN BRIEF: Destiny Pharma receives Europe watchdog XF-73 boost

IN BRIEF: Destiny Pharma receives Europe watchdog XF-73 boost

Destiny upbeat on nasal gel feedback from EMA

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Tuesday that it has received positive scientific advice from the European Medicines Agency (EMA), following its review of its proposed phase 3 clinical programme design.

Destiny successfully completes preclinical study of dermal formulation

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the successful completion of a preclinical safety study with a novel 'XF-73' dermal formulation on Tuesday.

Destiny Pharma reports success in US C. diff trial

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the successful outcome of its cooperative research and development agreement with the US Department of Veterans Affairs (VA) on Monday.

IN BRIEF: Destiny Pharma notes study that shows need for XF platform

IN BRIEF: Destiny Pharma notes study that shows need for XF platform

TRADING UPDATES: MP Evans declares special payout as production rises

TRADING UPDATES: MP Evans declares special payout as production rises

IN BRIEF: Destiny Pharma's Morgan to step down from board in March

IN BRIEF: Destiny Pharma's Morgan to step down from board in March

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru